From the experience of discovery of the first and best-in-class MEK inhibitor trametinib

Toshiyuki Sakai

9:50 AM - 10:05 AM

[1S09m-04] From the experience of discovery of the first and best-in-class MEK inhibitor trametinib

^○Toshiyuki Sakai (Department of Drug Discovery Medicine, Kyoto Prefectural University of Medicine)

キーテクノロジー：RB再活性化スクリーニング

トラメチニブ、創薬、産学連携

Contents of this site has moved to the member page of The Japanese Biochemical Society: https://member.jbsoc.or.jp/mypage/
You can access the abstracts without credentials by accessing them via the member page.

You need the membership number and password to access the member page. Please contact the journal office for any inquiries.

Journal Office Contact Information:
E-mail:jbs-ho@jbsoc.or.jp
Tel:03(3815)1913 Fax:03(3815)1934

The 92nd Annual Meeting of JBS

[1S09m-04] From the experience of discovery of the first and best-in-class MEK inhibitor trametinib

Password